Update on treatment in acute stage of Kawasaki disease.
10.3345/kjp.2008.51.5.457
- Author:
Ji Whan HAN
1
Author Information
1. Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. han59@catholic.ac.kr
- Publication Type:Review
- Keywords:
Refractory Kawasaki disease;
Adjuvant therapy
- MeSH:
Adrenal Cortex Hormones;
Aspirin;
Coronary Vessels;
Early Diagnosis;
Humans;
Mucocutaneous Lymph Node Syndrome;
Necrosis;
Pediatrics
- From:Korean Journal of Pediatrics
2008;51(5):457-461
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Kawasaki disease (KD) was first described by Dr. Tomisaku Kawasaki in his 1975 study, published in Pediatrics. Its pathogenesis is still not clearly understood. Early diagnosis and treatment are very important to preventing concomitant coronary artery complications. Most KD patients respond well to the standard treatment of aspirin and intravenous immunoglobulin; however, some of them are refractory to the standard treatment, and so adjuvant therapies with corticosteroids and anti-tumor necrosis factor-alpha (TNF-alpha) antibody are necessary. In this article, the author reviews and summarizes the most recent literature on the treatment of refractory KD.
